Export 11 results:
Author [ Title(Desc)] Type Year
Filters: Author is Antin, Joseph H  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
A
A. Krishnan, Pasquini, M. C., Logan, B., Stadtmauer, E. A., Vesole, D. H., Alyea, E., Antin, J. H., Comenzo, R., Goodman, S., Hari, P., Laport, G., Qazilbash, M. H., Rowley, S., Sahebi, F., Somlo, G., Vogl, D. T., Weisdorf, D., Ewell, M., Wu, J., Geller, N. L., Horowitz, M. M., Giralt, S., and Maloney, D. G., “Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial.”, Lancet Oncol, vol. 12, no. 13, pp. 1195-203, 2011.
B
M. C. Pasquini, Logan, B., Jones, R. J., Alousi, A. M., Appelbaum, F. R., Bolaños-Meade, J., Flowers, M. E. D., Giralt, S., Horowitz, M. M., Jacobsohn, D., Koreth, J., Levine, J. E., Luznik, L., Maziarz, R., Mendizabal, A., Pavletic, S., Perales, M. - A., Porter, D., Reshef, R., Weisdorf, D., and Antin, J. H., “Blood and Marrow Transplant Clinical Trials Network Report on the Development of Novel Endpoints and Selection of Promising Approaches for Graft-versus-Host Disease Prevention Trials.”, Biol Blood Marrow Transplant, vol. 24, no. 6, pp. 1274-1280, 2018.
F
J. Tolar, H Deeg, J., Arai, S., Horwitz, M., Antin, J. H., McCarty, J. M., Adams, R. H., Ewell, M., Leifer, E. S., Gersten, I. D., Carter, S. L., Horowitz, M. M., Nakamura, R., Pulsipher, M. A., Difronzo, N. L., Confer, D. L., Eapen, M., and Anderlini, P., “Fludarabine-based conditioning for marrow transplantation from unrelated donors in severe aplastic anemia: early results of a cyclophosphamide dose deescalation study show life-threatening adverse events at predefined cyclophosphamide dose levels.”, Biol Blood Marrow Transplant, vol. 18, no. 7, pp. 1007-11, 2012.
P
J. Bolaños-Meade, Logan, B. R., Alousi, A. M., Antin, J. H., Barowski, K., Carter, S. L., Goldstein, S. C., Hexner, E. O., Horowitz, M. M., Lee, S. J., Levine, J. E., MacMillan, M. L., Martin, P. J., Mendizabal, A. M., Nakamura, R., Pasquini, M. C., Weisdorf, D. J., Westervelt, P., and Ho, V. T., “Phase 3 clinical trial of steroids/mycophenolate mofetil vs steroids/placebo as therapy for acute GVHD: BMT CTN 0802.”, Blood, vol. 124, no. 22, pp. 3221-7; quiz 3335, 2014.
K. Ballen, Mendizabal, A. M., Cutler, C., Politikos, I., Jamieson, K., Shpall, E. J., Dey, B. R., Attar, E., McAfee, S., Delaney, C., McCarthy, P., Ball, E. D., Kamble, R., Avigan, D., Maziarz, R. T., Ho, V. T., Koreth, J., Alyea, E., Soiffer, R., Wingard, J. R., Boussiotis, V., Spitzer, T. R., and Antin, J. H., “Phase II trial of parathyroid hormone after double umbilical cord blood transplantation.”, Biol Blood Marrow Transplant, vol. 18, no. 12, pp. 1851-8, 2012.
M. Abu Zaid, Wu, J., Wu, C., Logan, B. R., Yu, J., Cutler, C., Antin, J. H., Paczesny, S., and Choi, S. Won, “Plasma biomarkers of risk for death in a multicenter phase 3 trial with uniform transplant characteristics post-allogeneic HCT.”, Blood, vol. 129, no. 2, pp. 162-170, 2017.
R
J. Pidala, Hamadani, M., Dawson, P., Martens, M., Alousi, A. M., Jagasia, M., Efebera, Y. A., Chhabra, S., Pusic, I., Holtan, S. G., Ferrara, J. L. M., Levine, J. E., Mielcarek, M., Anasetti, C., Antin, J. H., Bolaños-Meade, J., Howard, A., Logan, B. R., Leifer, E. S., Pritchard, T. S., Horowitz, M. M., and MacMillan, M. L., “Randomized multicenter trial of sirolimus vs prednisone as initial therapy for standard-risk acute GVHD: the BMT CTN 1501 trial.”, Blood, vol. 135, no. 2, pp. 97-107, 2020.
S
S. R. Walsh, Wilck, M. B., Dominguez, D. J., Zablowsky, E., Bajimaya, S., Gagne, L. S., Verrill, K. A., Kleinjan, J. A., Patel, A., Zhang, Y., Hill, H., Acharyya, A., Fisher, D. C., Antin, J. H., Seaman, M. S., Dolin, R., and Baden, L. R., “Safety and immunogenicity of modified vaccinia Ankara in hematopoietic stem cell transplant recipients: a randomized, controlled trial.”, J Infect Dis, vol. 207, no. 12, pp. 1888-97, 2013.
C. Cutler, Stevenson, K., Kim, H. T., Richardson, P., Ho, V. T., Linden, E., Revta, C., Ebert, R., Warren, D., Choi, S., Koreth, J., Armand, P., Alyea, E., Carter, S., Horowitz, M., Antin, J. H., and Soiffer, R., “Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation.”, Blood, vol. 112, no. 12, pp. 4425-31, 2008.
T
C. Cutler, Logan, B., Nakamura, R., Johnston, L., Choi, S., Porter, D., Hogan, W. J., Pasquini, M., MacMillan, M. L., Hsu, J. W., Waller, E. K., Grupp, S., McCarthy, P., Wu, J., Hu, Z. - H., Carter, S. L., Horowitz, M. M., and Antin, J. H., “Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT.”, Blood, vol. 124, no. 8, pp. 1372-7, 2014.
J. Bolaños-Meade, Reshef, R., Fraser, R., Fei, M., Abhyankar, S., Al-Kadhimi, Z., Alousi, A. M., Antin, J. H., Arai, S., Bickett, K., Bin Chen, Y. -, Damon, L. E., Efebera, Y. A., Geller, N. L., Giralt, S. A., Hari, P., Holtan, S. G., Horowitz, M. M., Jacobsohn, D. A., Jones, R. J., Liesveld, J. L., Logan, B. R., MacMillan, M. L., Mielcarek, M., Noel, P., Pidala, J., Porter, D. L., Pusic, I., Sobecks, R., Solomon, S. R., Weisdorf, D. J., Wu, J., Pasquini, M. C., and Koreth, J., “Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with”, Lancet Haematol, vol. 6, no. 3, pp. e132-e143, 2019.